Pharmacoproteomics Profile in Response to Acamprosate Treatment of an Alcoholism Animal Model

Caroline E. Germany, Ashlie N. Reker, David J. Hinton, Alfredo Oliveros, Xinggui Shen, Lindsey G. Andres-Beck, Katheryn M. Wininger, Marjan Trutschl, Urska Cvek, Doo Sup Choi, Hyung W. Nam

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Acamprosate is an FDA-approved medication for the treatment of alcoholism that is unfortunately only effective in certain patients. Although acamprosate is known to stabilize the hyper-glutamatergic state in alcoholism, pharmacological mechanisms of action in brain tissue remains unknown. To investigate the mechanism of acamprosate efficacy, the authors employ a pharmacoproteomics approach using an animal model of alcoholism, type 1 equilibrative nucleoside transporter (ENT1) null mice. The results demonstrate that acamprosate treatment significantly decreased both ethanol drinking and preference in ENT1 null mice compared to that of wild-type mice. Then, to elucidate acamprosate efficacy mechanism in ENT1 null mice, the authors utilize label-free quantification proteomics comparing both genotype and acamprosate treatment effects in the nucleus accumbens (NAc). A total of 1040 protein expression changes are identified in the NAc among 3634 total proteins detected. The proteomics and Western blot result demonstrate that acamprosate treatment decreased EAAT expression implicating stabilization of the hyper-glutamatergic condition in ENT1 null mice. Pathway analysis suggests that acamprosate treatment in ENT1 null mice seems to rescue glutamate toxicity through restoring of RTN4 and NF-κB medicated neuroimmune signaling compared to wild-type mice. Overall, pharmacoproteomics approaches suggest that neuroimmune restoration is a potential efficacy mechanism in the acamprosate treatment of certain sub-populations of alcohol dependent subjects.

Original languageEnglish (US)
Article number1700417
JournalProteomics - Practical Proteomics
Volume18
Issue number7
DOIs
StatePublished - Jan 1 2018
Externally publishedYes

Fingerprint

Alcoholism
Animals
Animal Models
Therapeutics
Nucleus Accumbens
Proteomics
Equilibrative Nucleoside Transporter 1
Molecular Mechanisms of Pharmacological Action
acamprosate
Drinking
Restoration
Toxicity
Labels
Glutamic Acid
Brain
Proteins
Ethanol
Stabilization
Western Blotting
Genotype

Keywords

  • acamprosate
  • alcoholism
  • bioinformatics
  • label-free proteomics
  • pharmacoproteomics

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology

Cite this

Germany, C. E., Reker, A. N., Hinton, D. J., Oliveros, A., Shen, X., Andres-Beck, L. G., ... Nam, H. W. (2018). Pharmacoproteomics Profile in Response to Acamprosate Treatment of an Alcoholism Animal Model. Proteomics - Practical Proteomics, 18(7), [1700417]. https://doi.org/10.1002/pmic.201700417

Pharmacoproteomics Profile in Response to Acamprosate Treatment of an Alcoholism Animal Model. / Germany, Caroline E.; Reker, Ashlie N.; Hinton, David J.; Oliveros, Alfredo; Shen, Xinggui; Andres-Beck, Lindsey G.; Wininger, Katheryn M.; Trutschl, Marjan; Cvek, Urska; Choi, Doo Sup; Nam, Hyung W.

In: Proteomics - Practical Proteomics, Vol. 18, No. 7, 1700417, 01.01.2018.

Research output: Contribution to journalArticle

Germany, CE, Reker, AN, Hinton, DJ, Oliveros, A, Shen, X, Andres-Beck, LG, Wininger, KM, Trutschl, M, Cvek, U, Choi, DS & Nam, HW 2018, 'Pharmacoproteomics Profile in Response to Acamprosate Treatment of an Alcoholism Animal Model', Proteomics - Practical Proteomics, vol. 18, no. 7, 1700417. https://doi.org/10.1002/pmic.201700417
Germany, Caroline E. ; Reker, Ashlie N. ; Hinton, David J. ; Oliveros, Alfredo ; Shen, Xinggui ; Andres-Beck, Lindsey G. ; Wininger, Katheryn M. ; Trutschl, Marjan ; Cvek, Urska ; Choi, Doo Sup ; Nam, Hyung W. / Pharmacoproteomics Profile in Response to Acamprosate Treatment of an Alcoholism Animal Model. In: Proteomics - Practical Proteomics. 2018 ; Vol. 18, No. 7.
@article{60939d62f028423883dbcc2f85da1b67,
title = "Pharmacoproteomics Profile in Response to Acamprosate Treatment of an Alcoholism Animal Model",
abstract = "Acamprosate is an FDA-approved medication for the treatment of alcoholism that is unfortunately only effective in certain patients. Although acamprosate is known to stabilize the hyper-glutamatergic state in alcoholism, pharmacological mechanisms of action in brain tissue remains unknown. To investigate the mechanism of acamprosate efficacy, the authors employ a pharmacoproteomics approach using an animal model of alcoholism, type 1 equilibrative nucleoside transporter (ENT1) null mice. The results demonstrate that acamprosate treatment significantly decreased both ethanol drinking and preference in ENT1 null mice compared to that of wild-type mice. Then, to elucidate acamprosate efficacy mechanism in ENT1 null mice, the authors utilize label-free quantification proteomics comparing both genotype and acamprosate treatment effects in the nucleus accumbens (NAc). A total of 1040 protein expression changes are identified in the NAc among 3634 total proteins detected. The proteomics and Western blot result demonstrate that acamprosate treatment decreased EAAT expression implicating stabilization of the hyper-glutamatergic condition in ENT1 null mice. Pathway analysis suggests that acamprosate treatment in ENT1 null mice seems to rescue glutamate toxicity through restoring of RTN4 and NF-κB medicated neuroimmune signaling compared to wild-type mice. Overall, pharmacoproteomics approaches suggest that neuroimmune restoration is a potential efficacy mechanism in the acamprosate treatment of certain sub-populations of alcohol dependent subjects.",
keywords = "acamprosate, alcoholism, bioinformatics, label-free proteomics, pharmacoproteomics",
author = "Germany, {Caroline E.} and Reker, {Ashlie N.} and Hinton, {David J.} and Alfredo Oliveros and Xinggui Shen and Andres-Beck, {Lindsey G.} and Wininger, {Katheryn M.} and Marjan Trutschl and Urska Cvek and Choi, {Doo Sup} and Nam, {Hyung W.}",
year = "2018",
month = "1",
day = "1",
doi = "10.1002/pmic.201700417",
language = "English (US)",
volume = "18",
journal = "Proteomics - Practical Proteomics",
issn = "1862-7595",
publisher = "Wiley-VCH Verlag",
number = "7",

}

TY - JOUR

T1 - Pharmacoproteomics Profile in Response to Acamprosate Treatment of an Alcoholism Animal Model

AU - Germany, Caroline E.

AU - Reker, Ashlie N.

AU - Hinton, David J.

AU - Oliveros, Alfredo

AU - Shen, Xinggui

AU - Andres-Beck, Lindsey G.

AU - Wininger, Katheryn M.

AU - Trutschl, Marjan

AU - Cvek, Urska

AU - Choi, Doo Sup

AU - Nam, Hyung W.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Acamprosate is an FDA-approved medication for the treatment of alcoholism that is unfortunately only effective in certain patients. Although acamprosate is known to stabilize the hyper-glutamatergic state in alcoholism, pharmacological mechanisms of action in brain tissue remains unknown. To investigate the mechanism of acamprosate efficacy, the authors employ a pharmacoproteomics approach using an animal model of alcoholism, type 1 equilibrative nucleoside transporter (ENT1) null mice. The results demonstrate that acamprosate treatment significantly decreased both ethanol drinking and preference in ENT1 null mice compared to that of wild-type mice. Then, to elucidate acamprosate efficacy mechanism in ENT1 null mice, the authors utilize label-free quantification proteomics comparing both genotype and acamprosate treatment effects in the nucleus accumbens (NAc). A total of 1040 protein expression changes are identified in the NAc among 3634 total proteins detected. The proteomics and Western blot result demonstrate that acamprosate treatment decreased EAAT expression implicating stabilization of the hyper-glutamatergic condition in ENT1 null mice. Pathway analysis suggests that acamprosate treatment in ENT1 null mice seems to rescue glutamate toxicity through restoring of RTN4 and NF-κB medicated neuroimmune signaling compared to wild-type mice. Overall, pharmacoproteomics approaches suggest that neuroimmune restoration is a potential efficacy mechanism in the acamprosate treatment of certain sub-populations of alcohol dependent subjects.

AB - Acamprosate is an FDA-approved medication for the treatment of alcoholism that is unfortunately only effective in certain patients. Although acamprosate is known to stabilize the hyper-glutamatergic state in alcoholism, pharmacological mechanisms of action in brain tissue remains unknown. To investigate the mechanism of acamprosate efficacy, the authors employ a pharmacoproteomics approach using an animal model of alcoholism, type 1 equilibrative nucleoside transporter (ENT1) null mice. The results demonstrate that acamprosate treatment significantly decreased both ethanol drinking and preference in ENT1 null mice compared to that of wild-type mice. Then, to elucidate acamprosate efficacy mechanism in ENT1 null mice, the authors utilize label-free quantification proteomics comparing both genotype and acamprosate treatment effects in the nucleus accumbens (NAc). A total of 1040 protein expression changes are identified in the NAc among 3634 total proteins detected. The proteomics and Western blot result demonstrate that acamprosate treatment decreased EAAT expression implicating stabilization of the hyper-glutamatergic condition in ENT1 null mice. Pathway analysis suggests that acamprosate treatment in ENT1 null mice seems to rescue glutamate toxicity through restoring of RTN4 and NF-κB medicated neuroimmune signaling compared to wild-type mice. Overall, pharmacoproteomics approaches suggest that neuroimmune restoration is a potential efficacy mechanism in the acamprosate treatment of certain sub-populations of alcohol dependent subjects.

KW - acamprosate

KW - alcoholism

KW - bioinformatics

KW - label-free proteomics

KW - pharmacoproteomics

UR - http://www.scopus.com/inward/record.url?scp=85058879703&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85058879703&partnerID=8YFLogxK

U2 - 10.1002/pmic.201700417

DO - 10.1002/pmic.201700417

M3 - Article

VL - 18

JO - Proteomics - Practical Proteomics

JF - Proteomics - Practical Proteomics

SN - 1862-7595

IS - 7

M1 - 1700417

ER -